The Carlyle Group Inc. 13D and 13G filings for eFFECTOR Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-05-13 4:05 pm Sale |
2024-05-09 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
Carlyle Group Inc. CG |
193,195 4.100% |
-1 (-0.00%) |
Filing |
| 2023-08-18 4:16 pm Unchanged |
2023-08-08 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
Carlyle Group Inc. CG |
193,196 7.800% |
0 (Unchanged) |
Filing |
| 2022-08-11 4:55 pm Purchase |
2022-08-01 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
Carlyle Group Inc. CG |
193,196 11.700% |
193,196 (New Position) |
Filing |